Dennis J. Phd Carlo Sells 13,292 Shares of Adamis Pharmaceuticals Corp (ADMP) Stock

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) CEO Dennis J. Phd Carlo sold 13,292 shares of the stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $2.27, for a total transaction of $30,172.84. Following the sale, the chief executive officer now directly owns 42,353 shares in the company, valued at $96,141.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of ADMP stock traded down $0.02 during trading hours on Monday, hitting $1.98. 182,186 shares of the company were exchanged, compared to its average volume of 406,219. Adamis Pharmaceuticals Corp has a 52 week low of $1.86 and a 52 week high of $5.10. The company has a market capitalization of $94.58 million, a price-to-earnings ratio of -1.98 and a beta of 1.40.

ADMP has been the topic of several research analyst reports. Zacks Investment Research cut shares of Adamis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, January 14th. Maxim Group set a $10.00 price objective on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, March 19th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $5.56.

Several hedge funds have recently modified their holdings of ADMP. Jane Street Group LLC bought a new position in Adamis Pharmaceuticals in the fourth quarter valued at $31,000. Cambridge Investment Research Advisors Inc. bought a new position in Adamis Pharmaceuticals in the fourth quarter valued at $36,000. Oppenheimer & Co. Inc. bought a new position in Adamis Pharmaceuticals in the fourth quarter valued at $38,000. Virtu Financial LLC bought a new position in Adamis Pharmaceuticals in the first quarter valued at $43,000. Finally, Barclays PLC bought a new position in Adamis Pharmaceuticals in the fourth quarter valued at $110,000. 17.60% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/15/dennis-j-phd-carlo-sells-13292-shares-of-adamis-pharmaceuticals-corp-admp-stock.html.

Adamis Pharmaceuticals Company Profile

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Recommended Story: Quick Ratio

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.